International Stem Cell Revenue Growth Rates (ISCO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
International Stem Cell Corporation  (ISCO)
 

ISCO's Revenue Growth by Quarter and Year

International Stem Cell's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ISCO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 2.68
1st Quarter March 2.32
FY 4.99

ISCOs Annual Revenue
International Stem Cell's Revenue in the fiscal year 2025 $ 9.10 millions
International Stem Cell's Revenue in the fiscal year 2024 $ 9.09 millions
International Stem Cell's Revenue in the fiscal year 2023 $ 7.79 millions
International Stem Cell's Revenue in the fiscal year 2022 $ 8.18 millions
International Stem Cell's Revenue in the fiscal year 2021 $ 7.18 millions




ISCO Revenue second quarter 2026 Y/Y Growth Comment
International Stem Cell Corporation reported Revenue growth of 9.18% year on year in the second quarter 2026, to $ 2.68 millions, this is lower than International Stem Cell Corporation's recent average Revenue increase of 12.65%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 106 other companies have achieved higher Revenue growth. While International Stem Cell Corporation' s Revenue increase of 9.18% ranks overall at the positon no. 1791 in the second quarter 2026.


ISCO Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -12.24 % 29.63 % -22.22 %
3rd Quarter September - 8.72 % 10.66 % 15.88 %
2nd Quarter June 9.18 % 5.15 % 26.63 % -9.36 %
1st Quarter March 8.92 % 0 % 1.91 % 3.47 %
FY   - 0.11 % 16.69 % -

Financial Statements
International Stem Cell's second quarter 2026 Revenue $ 2.68 millions ISCO's Income Statement
International Stem Cell's second quarter 2025 Revenue $ 2.45 millions Quarterly ISCO's Income Statement


ISCO Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -9.28 % 12.39 % -4.06 %
3rd Quarter September - -3.27 % -6.44 % 7.07 %
2nd Quarter June 15.3 % 15.02 % 9.39 % -11.96 %
1st Quarter March 7.91 % -13.06 % 12.7 % -13.99 %
FY (Year on Year)   - 0.11 % 16.69 % -


Back to ISCO Growth rate Comparisons >> Back to ISCO Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #107
Healthcare Sector #282
Overall #1791

Revenue Y/Y Growth Statistics
High Average Low
152.62 % 12.65 % -48.01 %
(Dec 31 2018)   (Mar 31 2021)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #107
Healthcare Sector #282
Overall #1791
Revenue Y/Y Growth Statistics
High Average Low
152.62 % 12.65 % -48.01 %
(Dec 31 2018)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

International Stem Cell's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
42.94 % 1.73 % -30.42 %
(Mar 31 2018)  


ISCO's II. Quarter Q/Q Revenue Comment
International Stem Cell Corporation achieved in the II. Quarter 2026 above company average sequential Revenue jump of 15.3%, to $ 2.68 millions, from $2.32 millions in the first quarter.
ISCO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While International Stem Cell's Revenue growth quarter on quarter, overall rank is 629.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #112
Overall #629
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #112
Overall #629
Revenue Q/Q Growth Statistics
High Average Low
42.94 % 1.73 % -30.42 %
(Mar 31 2018)  


ISCO's II. Quarter Q/Q Revenue Comment
International Stem Cell Corporation achieved in the II. Quarter 2026 above company average sequential Revenue jump of 15.3%, to $ 2.68 millions, from $2.32 millions in the first quarter.
ISCO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While International Stem Cell's Revenue growth quarter on quarter, overall rank is 629.


International Stem Cell's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 9.51 $ 9.29 $ 9.10 $ 9.39 $ 9.20
Y / Y Revenue Growth (TTM) 3.4 % 2.21 % 0.17 % 10.12 % 10.56 %
Year on Year Revenue Growth Overall Ranking # 2423 # 2977 # 1356 # 1259 # 883
Seqeuential Revenue Change (TTM) 2.46 % 2.04 % -3.1 % 2.06 % 1.28 %
Seq. Revenue Growth (TTM) Overall Ranking # 2423 # 2977 # 1356 # 1259 # 883


Cumulative Revenue growth Comment
Although International Stem Cell's Annual Revenue growth year on year were below company's average 7.54% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 3.4% year on year, from 2.21% in Mar 31 2026.

In the Healthcare sector 242 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2423, from total ranking in previous quarter at 2977.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 243
Overall # 1440

Revenue TTM Y/Y Growth Statistics
High Average Low
48.73 %
 7.54 %
-33.16 %
(Dec 31 2018)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 120
Sector # 360
S&P 500 # 2511
Cumulative Revenue growth Comment
Although International Stem Cell's Annual Revenue growth year on year were below company's average 7.54% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 3.4% year on year, from 2.21% in Mar 31 2026.

In the Healthcare sector 242 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2423, from total ranking in previous quarter at 2977.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 243
Overall # 1440

Revenue TTM Y/Y Growth Statistics
High Average Low
48.73 %
7.54 %
-33.16 %
(Dec 31 2018)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 120
Sector # 360
S&P 500 # 2511




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ISCO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Alpha Pro Tech Ltd 15.76%$ 15.765 millions
Armata Pharmaceuticals Inc 15.72%$ 15.722 millions
Lifeward ltd 15.71%$ 15.706 millions
Novocure Limited15.60%$ 15.603 millions
Ufp Technologies Inc 15.56%$ 15.558 millions
Orthopediatrics Corp15.55%$ 15.551 millions
Jazz Pharmaceuticals Plc15.55%$ 15.548 millions
Alphatec Holdings Inc 15.35%$ 15.349 millions
Penumbra Inc14.90%$ 14.904 millions
Rockwell Medical inc 14.69%$ 14.687 millions
Sbc Medical Group Holdings Incorporated14.36%$ 14.363 millions
Nuwellis Inc 14.14%$ 14.145 millions
West Pharmaceutical Services Inc 13.89%$ 13.892 millions
Edwards Lifesciences Corporation13.66%$ 13.657 millions
Indivior Pharmaceuticals Inc 13.58%$ 13.576 millions
Talkspace Inc 13.56%$ 13.556 millions
Atricure Inc 13.38%$ 13.376 millions
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions
Bausch Health Companies Inc 12.73%$ 12.727 millions
Vertex Pharmaceuticals Inc12.45%$ 12.453 millions
Genedx Holdings Corp 12.30%$ 12.304 millions
Profound Medical Corp 12.30%$ 12.302 millions
Xenetic Biosciences Inc 11.99%$ 11.986 millions
Biolife Solutions Inc 11.98%$ 11.978 millions
Repligen Corp11.93%$ 11.933 millions
Medline Inc 11.60%$ 11.603 millions
Earth Science Tech Inc 11.56%$ 11.556 millions
Immucell Corporation11.50%$ 11.501 millions
Harrow Inc 11.26%$ 11.256 millions


About International Stem Cell Revenue Growth Rates (ISCO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: International Stem Cell Corp (CIK 1355790).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-349108
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: International Stem Cell Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.